Low incidence of SARs-CoV-2 among IBD patients on biologic therapy

Investigators found a low incidence of SARs-CoV-2 among patients with inflammatory bowel disease who were taking biologic therapy, according to recently published data in the Journal of Gastroenterology and Hepatology.“Ultimately, the relatively low incidence of SARS-CoV-2 in IBD patients having biologic therapy may provide some reassurance to patients and clinicians for the continuation of these treatment methods,” Ming Hui Lee, MD, from the department of biological sciences, faculty of science at the National University of Singapore, and colleagues wrote. “Regardless,Read More

Share on facebook
Share on twitter
Share on linkedin